NMP-22 urine assays for bladder cancer – pro
NMP-22 urine assays for bladder cancer detect nuclear mitotic apparatus protein 1 (NUMA-1) using monoclonal antibodies. NMP-22 protein provides structural support for the nucleus and ensures the correct separation of genetic material during mitosis into the respective daughter cells through mitotic spindle stabilization. It is not a particularly specific tests, with many described non-cancer factors that elevate its values, and there is ongoing controversy as to whether its advantages in sensitivity over urine cytology are sufficient to recommend it as a routine screening test for bladder cancer.
Medicare has granted this test a CLIA exception but there are no guidelines that support its use at this time.
Huber S, Schwentner C, Taeger D, Pesch B, Nasterlack M, Leng G, Mayer T, Gawrych K, Bonberg N,
Pelster M, Johnen G, Bontrup H, Wellhäußer H, Bierfreund HG, Wiens C, Bayer C, Eberle F,
Scheuermann B, Kluckert M, Feil G, Brüning T, Stenzl A: UroScreen Study Group. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int 2012, 110(5):699-708
Todenhöfer T, Hennenlotter J, Witstruk M, Gakis G, Aufderklamm S, Kuehs U, Stenzl A, Schwentner C: Influence of renal excretory function on the performance of urine based markers to detect bladder cancer. J Urol 2012, 187(1):68-73.
For Lay version see here